Your browser doesn't support javascript.
loading
Differences in Tumor-Associated T cell receptor repertoires between Early-Onset and Average-Onset colorectal cancer.
Tsai, Ya-Yu; Nair, Kanika G; Barot, Shimoli V; Xiang, Shao; Kamath, Suneel; Melas, Marilena; Walker, Christopher P; Srivastava, Raghvendra; Osborne, Nicole; Chan, Timothy A; Mitchem, Jonathan B; Bonner, Joseph D; McDonnell, Kevin J; Idos, Gregory E; Sanz-Pamplona, Rebeca; Greenson, Joel K; Rennert, Hedy S; Rennert, Gad; Moreno, Victor; Gruber, Stephen B; Khorana, Alok A; Liska, David; Schmit, Stephanie L.
Afiliación
  • Tsai YY; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Nair KG; Cleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
  • Barot SV; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Xiang S; Cleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
  • Kamath S; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Melas M; Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA.
  • Walker CP; Cleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
  • Srivastava R; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Osborne N; Case Comprehensive Cancer Center, Cleveland, OH, USA.
  • Chan TA; Cleveland Clinic Lerner College of Medicine, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Mitchem JB; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
  • Bonner JD; Department of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.
  • McDonnell KJ; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Idos GE; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Sanz-Pamplona R; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Greenson JK; Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA.
  • Rennert HS; VA Northeast Ohio Health System, Cleveland, OH, USA.
  • Rennert G; Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA.
  • Moreno V; Department of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.
  • Gruber SB; Department of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.
  • Khorana AA; Department of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.
  • Liska D; Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain.
  • Schmit SL; ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
J Natl Cancer Inst ; 2024 Jun 20.
Article en En | MEDLINE | ID: mdl-38902947
ABSTRACT
The incidence of colorectal cancer (CRC) among individuals younger than age 50 (early onset CRC; EOCRC) has substantially increased, yet the etiology and molecular mechanisms underlying this alarming rise remain unclear. We compared tumor-associated T cell repertoires between EOCRC and average-onset CRC (AOCRC) to uncover potentially unique immune microenvironment-related features by age of onset. Our discovery cohort included 242 patients who underwent surgical resection at Cleveland Clinic from 2000 to 2020. EOCRC was defined as age < 50 years at diagnosis (N = 126), and AOCRC as age ≥ 60 years (N = 116). T cell receptor (TCR) abundance and clonality were measured by immunosequencing of tumors. Logistic regression models were used to evaluate the associations between TCR repertoire features and age of onset, adjusting for sex, race, tumor location, and stage. Findings were replicated in 152 EOCRC and 1,984 AOCRC cases from the Molecular Epidemiology of Colorectal Cancer Study. EOCRC tumors had significantly higher TCR diversity compared to AOCRC tumors in the discovery cohort (Odds Ratio (OR)0.44, 95% Confidence Interval (CI)0.32-0.61, p < .0001). This association was also observed in the replication cohort (OR 0.74, 95% CI 0.62-0.89, p = .0013). No significant differences in TCR abundance were observed between EOCRC and AOCRC in either cohort. Higher TCR diversity, suggesting a more diverse intratumoral T cell response, is more frequently observed in EOCRC than AOCRC. Further studies are warranted to investigate the role of T cell diversity and the adaptive immune response more broadly in the etiology and outcomes of EOCRC.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Natl Cancer Inst Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Natl Cancer Inst Año: 2024 Tipo del documento: Article